Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Effect of Mixing Iodinated Contrast Media and Ultrasound Contrast Agents on Subharmonic Signals
Esposito, Cara , Tzan, Kenneth, Machado, Priscilla , Forsberg, Flemming , Dave, Jaydev K. , Dave, Jaydev K

Mayo Clinic

Ultrasonic Imaging | February 6, 2024 | Volume: 46 | Issue: 2 | Pages: 130-134

10.1177/01617346241227971 | PMID 38318708 Get It

Subharmonic aided pressure estimation (SHAPE) is a technique that utilizes subharmonic signals from microbubble contrast agents for pressure estimation. Validation of the SHAPE technique relies on synchronous measurements of in vivo pressures using contrast microbubbles and a pressure catheter (reference standard). For the guidance and placement of pressure catheter in vivo, iodinated contrast is used with fluoroscopy. Therefore, during data acquisition for validation studies of the SHAPE technique, both contrast microbubbles and iodinated contrast are present simultaneously within the vasculature. This study aims to elucidate the effects of iodinated contrast (Visipaque, GE HealthCare) on subharmonic signal amplitude from contrast microbubbles (Definity, Lantheus Medical Imaging, Inc.). In an acrylic water tank, 0.06 mL of Definity and varied amounts of Visipaque (0.14, 0.43, 0.85, and 1.70 mL) were added to 425 mL of deionized water. Ultrasound scanning was performed with a SonixTablet scanner (BK Medical Systems) using optimized parameters for SHAPE with Definity ( f transmit/receive = 3.0/1.5 MHz; chirp down pulse). Subharmonic data was acquired and analyzed at 9 different incident acoustic outputs ( n = 3). Results showed an increase in subharmonic signal amplitude from Definity microbubbles in the presence of 0.14 mL Visipaque by 2.8 ± 1.3 dB ( p < .001), no change with 0.85 mL Visipaque (0.7 ± 1.2 dB; p = .09) and a decrease in subharmonic amplitude in the presence of 1.70 mL Visipaque by 1.9 ± 0.7 dB ( p < .001). While statistically significant effect on subharmonic signal amplitude of Definity microbubbles was noted due to the mixture, the magnitude of the effect was minimal (~2.8 dB) and unlikely to impact in vivo SHAPE measurements.
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
Samples, Laura , Fakhri, Bita , Khajavian, Sirin, Spurgeon, Stephen E. , Stephens, Deborah M. , Skarbnik, Alan P , Mato, Anthony R. , Broome, Catherine M. , Gopal, Ajay K. , Smith, Stephen D. , Lynch, Ryan C. , Rainey, Magdalena A., Barrett-Campbell, Odeth, Hemond, Emily, Malakhov, Nikita , Rao, Danielle, Shakib-Azar, Mehrdad, Morrigan, Beth, Chauhan, Ayushi , Plate, Thomas , Gooley, Ted, Ryan, Kellie, Hill, Brian T. , Pongas, Georgios , Allan, John N. , Cheng, Richard K. , Ujjani, Chaitra S. , Fakhri, Bita , Stephens, Deborah M , Gopal, Ajay , Smith, Stephen D , Rainey, Magdalena , Tsang, Mazie , Chauhan, Ayushi , Lansigan, Frederick , Parikh, Sameer A , Roeker, Lindsey , Allan, John N , Cheng, Richard , Ujjani, Chaitra , Voutsinas, Jenna M. , Kim, Myung Sun , Tsang, Mazie , Ermann, Daniel A. , Lansigan, Frederick , Parikh, Sameer A. , Roeker, Lindsey E. , Shadman, Mazyar

Mayo Clinic

Blood Advances | February 5, 2024 | Volume: 8 | Issue: 9 | Pages: 2085-2093

10.1182/bloodadvances.2023011569 | PMID 38315043 Get It

Abstract Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new or worsening hypertension (HTN). Little is known about the optimal treatment of BTKi-associated HTN. Randomly selected patients with lymphoid malignancies on a BTKi and antihypertensive drug(s) and with at least 3 months of follow-up data were sorted into 2 groups: those diagnosed with HTN before BTKi initiation (prior-HTN), and those diagnosed with HTN after BTKi initiation (de novo HTN). Generalized estimating equations assessed associations between time varying mean arterial pressures (MAPs) and individual anti-HTN drug categories. Of 196 patients included in the study, 118 had prior-HTN, and 78 developed de novo HTN. Statistically significant mean MAP reductions were observed in patients with prior-HTN who took β blockers (BBs) with hydrochlorothiazide (HCTZ), (−5.05 mmHg; 95% confidence interval [CI], 10.0 to −0.0596; P = .047), and patients diagnosed with de novo HTN who took either an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) with HCTZ (−5.47 mmHg; 95% CI, 10.9 to −0.001; P = .05). These regimens also correlated with the greatest percentages of normotensive MAPs. Treatment of HTN in patients taking a BTKi is challenging and may require multiple antihypertensives. Patients with prior-HTN appear to benefit from combination regimens with BBs and HCTZ, whereas patients with de novo HTN appear to benefit from ACEi/ARBs with HCTZ. These results should be confirmed in prospective studies.
Abstract WP215: Number of Passes Matter in Acute Ischemic Stroke Patients Who Underwent Failed Mechanical Thrombectomy
Uchida, Kazutaka , Maier, Ilko , Kasab, Sami Al , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Levitt, Michael , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Elawady, Sameh Samir , Cunningham, Conor M. , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Zandpazandi, Sara , Orscelik, Atakan , Jabbour, Pascal , Psychogios, Marios‐Nikos , Shaban, Amir , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael, Williamson, Richard, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp215 Get It

Introduction: Acute ischemic stroke (AIS) patients often require multiple passes during mechanical thrombectomy (MT) to open the vessel. Yet, at times, even numerous passes are unsuccessful. This study aims to investigate the impact of the number of passes on the outcomes of patients who underwent failed MT. Methods: We used Data from the Stroke Thrombectomy and Aneurysm Registry (STAR) from 2013 to August 2023. Patients who underwent MT for ICA, M1, or M2 with unsuccessful recanalization (modified Thrombolysis in Cerebral Infarction ≤ 2a) were included. Primary outcome was 90- day modified Rankin Scale (mRS) 0-2. Secondary outcomes included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH). Outcomes were compared among patients who received ≤ 2, 3, 4, and ≥ 5 MT passes. Results: 736 patients met inclusion criteria. 90-day mRS 0-2 was found to decrease with number of passes (Figure 1). Multivariate logistic regression analysis revealed that 3 passes (OR: 0.48, 95% CI: 0.23 -0.96, P-value: 0.04), 4 passes (OR: 0.46, 95% CI: 0.19 -1.03, P-value: 0.07), and ≥ 5 passes (OR: 0.22, 95% CI: 0.08 -0.50, P-value: <0.001) were associated with lower odds of mRS 0-2 compared to ≤ 2 passes. However, there were no significant differences between groups in ICH, sICH, or 90-day mortality. Conclusion: The number of passes affects functional outcomes among stroke patients who underwent failed MT.
Abstract WP205: Development and Validation of a Prediction Model for Outcome in Mechanical Thrombectomy for Large-Vessel Occlusion Anterior Circulation Stroke With Low ASPECTS
Uchida, Kazutaka , Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Grossberg, Jonathan A , Tanweer, Omar , Polifka, Adam , Matouk, Charles, Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Matsukawa, Hidetoshi , Elawady, Sameh Samir , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Psychogios, Marios‐Nikos , Shaban, Amir , Arthur, Adam Stephen , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Yoshimura, Shinichi

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp205 Get It

Introduction: Recent randomized control trials suggested that mechanical thrombectomy (MT) was associated with good functional outcomes after acute ischemic stroke (AIS) due to large vessel occlusion (LVO) in patients presenting with low Alberta Stroke Program Early CT Score (ASPECTS) (defined as ASPECTS 2-5). The aim of this study is to develop and validate a stroke prediction tool for outcome in MT for AIS patients with low ASPECTS using data from an ongoing international multicenter registry, the Stroke Thrombectomy and Aneurysm Registry (STAR). Methods: 236 AIS patients with low ASPECTS caused by LVO who undertook MT between January 2010 and December 2022 were retrospectively investigated. Univariate and multivariate logistic regression results were used to screen model predictors and construct nomograms of 90-day modified Rankin Scale scores (mRS) 0-3. The performance of the model was detected by using receiver operating characteristic analysis. The bootstrap resampling method was considered internal validation of the model. Results: Age (< 70 years), premorbid status (mRS 0), National Institutes of Health Stroke Scale (NIHSS) (< 20), and recanalization status after the MT (modified Thrombolysis in Cerebral Ischemia [mTICU] ≥2b) were related to 90-day mRS 0-3. Predictive score was calculated by adding 1 point for age (< 70 years), premorbid status (mRS 0), and NIHSS < 20 and 3 points for a mTICI ≥2b (ranging 0-6). 90-day mRS 0-3 was observed in 0% of patients with a score of 0 or 1, 6.3% with a score of 2, 17.7% with a score of 3, 22.2% with a score of 4, 45.7% with a score of 5, and 73.7% with a score of 6. The score showed relatively high performance in predicting 90-day mRS0-3 (area under the curve: 0.79 [95% CI 0.73-0.79] and 0.78 [95% CI 0.78-0.78] for derivation and validation cohorts, respectively). Conclusions: This study indicates the STAR score can be calculated with baseline and periprocedural characteristics to predict the 90-day outcome after MT in AIS patients with low ASPECTS.
Abstract WP192: Impact of Second Line Thrombectomy Technique Following Failed First Pass Thrombectomy for Anterior Circulation Stroke: To Switch or Not to Switch?
Uchida, Kazutaka , Kasab, Sami Al , Maier, Ilko , Kim, Joon‐Tae , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Tanweer, Omar , Polifka, Adam , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Matsukawa, Hidetoshi , Alawieh, Ali , Matouk, Charles , Sowlat, Mohammad‐Mahdi , Elawady, Sameh Samir , Jabbour, Pascal , Wolfe, Stacey Q , Samaniego, Edgar A , Arthur, Adam Stephen , Cuellar, Hugo , Howard, Brian M , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Yoshimura, Shinichi

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp192 Get It

Introduction: Despite comparable outcomes for different frontline techniques in mechanical thrombectomy (MT) for acute ischemic stroke (AIS), there are sparse data regarding if and when to switch techniques if the first pass is unsuccessful. We aimed to investigate the impact of converting from one MT technique to another on the second MT attempt for AIS among patients with large vessel occlusion (LVO). Methods: This was a retrospective observational study using data from the large multicenter international Stroke Thrombectomy and Aneurysm Registry (STAR). Data from 29 stroke centers for 10,229 AIS patients treated with MT for LVO between January 2010 and December 2022 was investigated. The primary outcome measure was successful recanalization defined as modified Thrombolysis in Cerebral Ischemia (mTICI) score of 2b or higher. 90-day modified Rankin score (mRS) 0-2, mortality and symptomatic hemorrhage were used as secondary outcomes. Clinical and technical outcomes after the second MT attempt were compared between those with or without technique conversion. Results: Among 10,229 AIS patients, 1,797 AIS patients with LVO failed first pass recanalization and were included in this retrospective analysis. 927 patients were female (52%) and median (interquartile range) age was 72 (61-81) years. Converting to alternative techniques following a first failed attempt was more likely to be associated with successful recanalization at the second attempt (adjusted odds ratio 2.30, 95% CI: 1.37-3.86, P = 0.002) and 90-day good clinical outcome (adjusted odds ratio 2.10, 95% CI: 1.15-3.85, P = 0.02) after multivariate adjustment. Conclusions: This study demonstrates better clinical and technical outcomes with conversion of MT technique for the second attempt in AIS patients with LVO who failed first pass recanalization.
Abstract WP184: Intravenous Thrombolysis Improves Outcomes in Stroke Patients With Unsuccessful Mechanical Thrombectomy
Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Levitt, Michael , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Elawady, Sameh Samir , Nawabi, Noah L. A. , Matsukawa, Hidetoshi , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Orscelik, Atakan , Zandpazandi, Sara , Jabbour, Pascal , Psychogios, Marios‐Nikos , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael, Williamson, Richard, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp184 Get It

Introduction: The benefits of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with unsuccessful mechanical thrombectomy (MT) are not well established. Methods: This study included patients from the Stroke Thrombectomy and Aneurysm Registry (STAR) who underwent MT for ICA, M1, or M2 occlusions with unsuccessful MT (mTICI score ≤ 2a). Patients who received IVT prior to MT were compared to those who received MT alone. Propensity score (PS) matching was performed using age, sex, premorbid modified Rankin Scale (mRS), admission National Institute of Health Stroke Scale (NIHSS), occluded vessel, ASPECTS score, mTICI score, and symptom onset to groin puncture time. The primary outcome was favorable 90-day outcomes (mRS 0-2). Results: Of 610 patients with unsuccessful MT, 219 were matched in each group. Median ages were 70 [IQR: 61 - 80] and 73 [IQR: 62 - 81] in the IVT + MT and MT alone groups, respectively. In the IVT + MT group. Final TICI scores of 0, 1, and 2a were achieved in 92 (42.0%), 33 (15.1%), and 94 (42.9%) patients, respectively, compared to 76 (34.7%), 29 (13.2%), and 114 (52.1%) in the MT alone group. The IVT + MT group showed a significantly. higher 90-day mRS of 0-2 (aOR: 2.54, 95% CI: 1.53-4.32) and mRS of 0-3 (aOR: 2.05, 95% CI: 1.36-3.12). There were no significant differences between the groups in intracranial hemorrhage (ICH), symptomatic ICH, or 90-day mortality rates. Conclusions: IVT is associated with improved functional outcomes in patients with unsuccessful MT. Ensuring that IVT is provided to all eligible stroke patients should remain a priority.
Abstract WP180: Novel Machine Learning Model for Prediction of Futile Recanalization in Acute Ischemic Stroke Patients With Anterior Circulation Large Vessel Occlusion
Uchida, Kazutaka , Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Cunningham, Conor M. , Zohdy, Youssef M. , Elawady, Sameh Samir , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Zandpazandi, Sara , Orscelik, Atakan , Jabbour, Pascal , Psychogios, Marios‐Nikos , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp180 Get It

Introduction: Up to 50% of acute ischemic stroke (AIS) patients who undergo successful mechanical thrombectomy (MT) fail to achieve favorable outcomes (futile recanalization). In this study we aim to develop a machine learning (ML) model to predict futile recanalization (FR) in AIS patients who undergo MT. Methods: We used data from an ongoing large, multicenter database from 2013 to 2023. We included AIS patients treated with MT for ICA, M1, or M2 occlusion with successful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] score ≥ 2C) and procedure durations under 60 minutes. FR was defined as successful recanalization with 90-day modified Rankin Scale (mRS) 3-6. The dataset was divided into 75% for training and 25% for external validation. Using the Caret Package in R, multiple models were tested, and their performances were evaluated by the area under the curve (AUC) of receiver operating. Both baseline and pre-interventional characteristics were incorporated into the model. The selected model was then externally validated on a 25% validation dataset. Results: Among 2,546 qualified patients, FR occurred in 1,342 (52.7%). In univariate analysis, baseline characteristics were significantly different between FR and non-FR groups. The M5P model demonstrated the highest performance (AUC: 0.833; 95% CI: 0.7989-0.852; PPV: 0.8101) in comparison to other tested models such as logistic regression (AUC: 0.74), RF (AUC: 0.78), J48 (AUC: 0.78), SVM (AUC: 0.79), and GB (AUC: 0.79). The external validation of the model showed satisfactory results (AUC: 75.25; 95% CI: 70-80; PPV: 76.87). Conclusion: Utilizing clinical, pre-procedural, and imaging parameters, the M5P model can efficiently predict F) in AIS patients before attempting MT. This tool can assist neurointerventionalists in adequately choosing their MT candidates.
Abstract TP5: Impact of Race on Outcomes in the Endovascular and Microsurgical Treatment in Patients With Intracranial Aneurysms: Analysis of the Stroke Thrombectomy and Aneurysm Registry
Uchida, Kazutaka , Kasab, Sami Al , Jabbour, Pascal , Brinjikji, Waleed , Burkhardt, Jan‐Karl , Ezzeldin, Mohamad , Kan, Peter , Moss, Mark, Spiotta, Alejandro M , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Elawady, Sameh Samir , Cunningham, Conor M. , Alawieh, Ali , Jabbour, Pascal , Mascitelli, Justin R , Levitt, Michael R. , Cuellar, Hugo , Samaniego, Edgar A , Fox, W Christopher , Grandhi, Ramesh , Altschul, David , Yoshimura, Shinichi

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tp5 Get It

Introduction: Impact of race on outcomes in the treatment of intracranial aneurysm (IA) remains unclear. We aimed to investigate the relationship between race classified into White, Black, Hispanic, and other ("other" includes Native American or Alaska Native, Asian or Pacific Islander, and other race) and treatment outcomes in patients with ruptured and unruptured IAs. Methods: Stroke Thrombectomy and Aneurysm Registry (STAR) was a retrospective observational study. Data from 9 centers in the United States, Europe, and Asia for IA patients who undertook endovascular treatment (EVT) or microsurgical treatment (MST) between January 2016 and December 2020 were included for analysis. The primary outcome was 90-day mRS 0-2. Secondary outcomes included periprocedural cerebral infarction and intracranial hemorrhage, perioperative symptomatic cerebral vasospasm in ruptured IA and mortality, and all causes of mortality within 90 days. Results: 2,836 IA patients treated with EVT or MST were included. Among these 2,836 patients, 1,053 patients were White, 350 were Black, 264 were Hispanic, and 1,169 were other. The primary outcome in Hispanic patients was significantly lower than White patients (adjusted odds ratio [aOR] 0.36, 95% CI, 0.23-0.56, P < .001). The periprocedural cerebral infarction, perioperative mortality, and all causes of mortality in Hispanic patients were significantly higher than White patients (aOR 2.53, 95% CI, 1.40-4.58, P = .002, aOR 1.84, 95% CI, 1.00-3.38, P = .049, aOR 1.83, 95% CI, 1.06-3.17, P = .03, respectively). However, these outcomes were not significantly different in Black and other patients compared to White patients. Conclusions: This study demonstrates Hispanic IA patients are more likely to have a poor outcome at 90 days following EVT or MST than White patients.
Abstract TP35: A 2-Stage Recruitment Design to Reduce MRI Screening Costs for a Theoretical Clinical Trial of WMH Progression
Egle, Marco , Jack, Clifford R. , Jack, Clifford R , Power, Melinda C. , Deal, Jennifer A. , Sullivan, Kevin , Mosley, Thomas H. , Gottesman, Rebecca F.

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tp35 Get It

Background: White matter hyperintensities (WMH) are associated with risk of dementia and stroke, so are an important therapeutic target for clinical trials. The cost of broad MRI screening to identify those individuals with significant WMH, however, limits the feasibility of designing clinical trials which target WMH presence and which test treatments that slow progression. Hypothesis: A low-cost retinal or clinical screening measure prior to an MRI screening stage reduces the cost of recruiting persons with significant WMH burden in a hypothetical clinical trial vs an MRI-only screening design. Method: Data were from participants in the Atherosclerosis Risk in Communities-Neurocognitive study with clinical, retinal and WMH measurements ( N = 1311) at ages 53-70 years. Significant WMH burden was defined as a Cardiovascular Health Study score >2. Three low-cost pre-screening measures were assessed: (1) retinal: a score incorporating multiple markers of abnormal retinal vasculature, (2) clinical: a score incorporating hypertension, diabetes, and age, (3) combined retinal-clinical: a score incorporating retinal and clinical factors. Given a prior published target sample for a WMH clinical trial (N= 646), we calculated a theoretical screening sample size based on the proportion of each pre-screening measure in the population multiplied by the proportion of significant WMH burden among those with a prevalent pre-screening feature. Total recruitment cost was calculated using standard retinal ($32.50) and MRI ($650) cost estimates. Results: Compared to the estimated cost of MRI-only screening (>$4.24M, requiring MRI screening 6,526 participants), pre-screening for a high clinical score reduced total cost to $2.47M, but increased the initial screening group to 52,778 participants, of whom 3,801 would be screened by MRI). A high retinal-clinical score cutoff reduced costs to $2.9M while only requiring 13,572 screened participants (of these only 3,801 would require MRI). Conclusion: A 2-stage recruitment design with a low-cost pre-screening retinal and clinical measure is a promising approach, resulting in a reduction of theoretical recruitment costs for recruiting persons with significant WMH burden compared to an MRI-only design.
Abstract TP219: Outcomes and Differences by Occluded Vessel in the Endovascular Treatment for Acute Ischemic Stroke Patients With Medium Vessel Occlusion
Uchida, Kazutaka , Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Grossberg, Jonathan A , Tanweer, Omar , Polifka, Adam , Matouk, Charles, Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Matsukawa, Hidetoshi , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Elawady, Sameh Samir , Jabbour, Pascal , Wolfe, Stacey Q , Psychogios, Marios‐Nikos , Shaban, Amir , Arthur, Adam Stephen , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Levitt, Michael R. , Williamson, Richard, Navía, Pedro , Leacy, Reade De , Yoshimura, Shinichi

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tp219 Get It

Introduction: The outcomes of mechanical thrombectomy (MT) for patients with acute ischemic stroke (AIS) caused by medium vessel occlusions (MeVOs) in different vessels remains unknown. The aim of this study is to investigate MT outcomes in AIS patients with isolated MeVOs in different occluded vessel segments using the data from an ongoing international multicenter registry, the Stroke Thrombectomy and Aneurysm Registry (STAR). The aim of this study is to investigate MT outcomes in AIS patients with isolated MeVOs in different occluded vessel segments using the data from an ongoing international multicenter registry, the Stroke Thrombectomy and Aneurysm Registry (STAR). Methods: 110 AIS patients with MeVO who undertook MT between January 2010 and December 2022 were retrospectively investigated. MeVO was defined as isolated occlusion of the A2 or A3 (A23O) segment of the anterior cerebral artery, M3 segment of the middle cerebral artery (M3O), and P2 or P3 segment of the posterior cerebral artery (P23O). The primary outcome measure was a 90-day modified Rankin score (mRS) 0-2. The 90-day mRS 0-1, any intracranial hemorrhage, symptomatic intracranial hemorrhage, and 90-day mortality were used as secondary outcomes. Outcomes were compared between A23O, M3O, and P23O. Results: Median (interquartile range) age was 68.3 (58.4-76.0) years and 49 patients were female (46.7%). MeVO included 17 A23O (15.5%), 60 M3O (54.5%), and 33 P23O (30.0%).Compared to patients with A23O (17.7%), those with M3O (56.7%) and P23O (45.5%) had a higher proportion of 90-day mRS 0-2 (M3O, adjusted odds ratio 10.3, 95% confidence interval 1.71-62.2, p = 0.01; P23O adjusted odds ratio 8.86, 95% confidence interval 1.32-59.3, p =0.02). Other outcomes showed no significant differences. Conclusions: This study indicates A2O might be related to poorer outcomes compared to M3O and P23 in MT treatment for AIS patients due to isolated MeVO. Efforts should be aimed at improving outcomes following A23O to match those at other MeVO locations.